Abstract: The invention relates generally to the field of compositions including one or more conjugates of di-sugar and a nonsteroidal anti-inflammatory drug (NSAID), and use of same in methods for treating a disease or a disorder in a subject in need thereof.

Abstract: A method of determining a type of a brain dysfunction is discloses. The method may include: receiving an electroencephalogram (EEG) signal from an electrode placed on the head; calculating a regularity index for an electric activity of the brain based on EEG signal; detecting a temporal change in the regularity index; receiving a medical related input; and determining the type of brain dysfunction based on the temporal change in the regularity index and the medical related input.

Abstract: Provided is reward system activation for therapeutic purposes. Accordingly there is provided a method of treating a disease in a subject in need thereof, the method comprising subjecting the subject to a treatment module which activates the reward system of the subject.

Abstract: A system and method of speech modification may include: receiving a recorded speech, comprising one or more phonemes uttered by a speaker; segmenting the recorded speech to one or more phoneme segments (PS), each representing an uttered phoneme; selecting a phoneme segment (PSk) of the one or more phoneme segments (PS); extracting a portion of the recorded speech, said portion corresponding to a first timeframe ({tilde over (T)}) that comprises the selected phoneme segment; receiving a representation () of a phoneme of interest P*; and applying a machine learning (ML) model on (a) the extracted portion of the recorded speech and (b) on the representation () of the phoneme of interest P*, to generate a modified version of the extracted portion of recorded speech, wherein the phoneme of interest (P*) substitutes the selected phoneme segment (PSk).

Abstract: A system for generating cold plasma is presented, suitable for use in in-vivo treatment of biological tissue. The system comprising: a control unit connectable to an elongated member at a first proximal end of the elongated member. The elongated member comprises a plasma generating unit at a second distal end thereof and gas and electricity transmission channels extending from said first proximal end towards said plasma generating unit. The control unit comprises a gas supply unit configured to provide predetermined flow rate of selected gas composition through said gas transmission channel and a power supply unit configured to generate selected sequence of high-frequency electrical pulses, typically in mega Hertz range, directed through said electricity transmission channel, thereby providing power and gas of said selected composition to the plasma generating unit for generating cold plasma.

Abstract: There is provided procoagulant peptides, and use of same, such as in treatment of hemostasis-related diseases or disorders, and/or wound healing.

Abstract: A system and method of predicting propensity of metastasis of a tumor in a patient by at least one processor may include: receiving, from a first scan modality, a first scan comprising a set of scan images depicting metabolic information; receiving, from a second scan modality, a second scan comprising a set of scan images depicting anatomical information; segmenting the first scan to identify a volumetric segment representing a suspected tumor, based on the depicted metabolic information; extracting one or more radiomics features from the second scan, corresponding to the volumetric segment, based on the depicted anatomical information; and predicting propensity of metastasis of the suspected tumor, based on the one or more radiomics features.

Abstract: A method of analyzing the therapeutic efficacy of a therapeutic agent for treating an immune-related disorder is disclosed. The method comprises contacting blood cells of the subject with the agent, measuring the expression of at least 20 genes in the blood cells of the subject; obtaining an immune age value based on the expression of the at least 20 genes, and comparing the immune age value with an immune age value of the subject calculated on the basis of expression of the at least 20 genes in blood cells of the subject, in the absence of the agent.

Abstract: Systems and methods of predicting glottal insufficiency by at least one hardware processor including receiving a voice recording comprising a phonation by a subject, analysis of the voice recording to calculate a fundamental frequency contour curve of the phonation, and measurement of at least one of (i) a time period from a start of the phonation until the contour curve reaches a settled level, (ii) a slope of the contour curve during the time period, and (iii) an area under the contour curve during that time period. In certain embodiments, the processor subsequently, determines a glottal closure insufficiency in the subject based on these measurements.

Abstract: The present invention provides methods for determining malignancy in a cyst by measuring viscosity of cyst fluid while under stain. The invention further provides devices, and computer program products for determining same.

Abstract: The present invention relates to an inhibitory peptide capable of disrupting a Heparanase/Tissue Factor complex. The invention further provides methods and kits for determining heparanase procoagulant activity in a biological sample. The invention also relates to diagnostic methods for the detection and/or monitoring of a coagulation-related pathologic disorder in a mammalian subject. The invention further relates to compositions comprising heparanase and at least one tissue factor, uses and methods based thereon in the treatment, amelioration and prevention of coagulation-related pathologic conditions. The invention still further relates to methods for screening a coagulation modulatory compound, methods and uses based thereon in the treatment, amelioration and prevention of coagulation-related pathologic conditions.

Abstract: A system for generating cold plasma is presented, suitable for use in in-vivo treatment of biological tissue. The system comprising: a control unit connectable to an elongated member at a first proximal end of the elongated member. The elongated member comprises a plasma generating unit at a second distal end thereof and gas and electricity transmission channels extending from said first proximal end towards said plasma generating unit. The control unit comprises a gas supply unit configured to provide predetermined flow rate of selected gas composition through said gas transmission channel and a power supply unit configured to generate selected sequence of high-frequency electrical pulses, typically in mega Hertz range, directed through said electricity transmission channel, thereby providing power and gas of said selected composition to the plasma generating unit for generating cold plasma.

Abstract: A pharmaceutical composition and a method of treating, reducing or preventing vascular, cardiovascular arterial or valve calcification in a subject in need comprising administering to the subject an effective amount of an agent that prevents or reduces the expression of HDAC4, an agent that modulates the location of HDAC4, an agent that binds to HDAC4 or an inhibitor of HDAC4 or any combination thereof is provided. In some embodiments, there is provided a pharmaceutical composition comprising: an agent that prevents or reduces the expression of HDAC4, an agent that modulates the location of HDAC4, an agent that binds to HDAC4 or an inhibitor of HDAC4 or any combination thereof; an agent that prevents or reduces the expression of SIK or is an inhibitor of SIK; and/or an agent that prevents or reduces the expression of ENIGMA (Pdlim7) or is an inhibitor of ENIGMA.

Abstract: A system for generating cold plasma is presented, suitable for use in in-vivo treatment of biological tissue. The system comprising: a control unit connectable to an elongated member at a first proximal end of the elongated member. The elongated member comprises a plasma generating unit at a second distal end thereof and gas and electricity transmission channels extending from said first proximal end towards said plasma generating unit. The control unit comprises a gas supply unit configured to provide predetermined flow rate of selected gas composition through said gas transmission channel and a power supply unit configured to generate selected sequence of high-frequency electrical pulses, typically in mega Hertz range, directed through said electricity transmission channel, thereby providing power and gas of said selected composition to the plasma generating unit for generating cold plasma.

Abstract: Provided are methods and kits for determining predisposition of a subject to develop a kidney disease, by identifying in a sample of the subject at least one APOL1 polypeptide variant which is characterized by a higher trypanolytic activity on Trypanosoma brucei rhodesiense as compared to the trypanolytic activity of wild type APOL1 polypeptide as set forth in SEQ ID NO:1 on the Trypanosoma brucei rhodesiense under identical assay conditions; or at least one APOL1 nucleotide mutation in the APLO1 genomic sequence set forth in SEQ ID NO:3, wherein the at least one nucleotide mutation or polypeptide variant being in linkage disequilibrium (LD) with the S342G mutation in the APOL1 polypeptide set forth in SEQ ID NO:1, wherein presence of the APOL1 polypeptide variant indicates increased predisposition of the subject to develop the kidney disease.

Abstract: The present invention relates, according to some embodiments, method of treating eye diseases, such as AMD by administering Semaphorin 3C (Sema3C) or a variant thereof having amino acid modifications at furin-like pro-protein convertase cleavage sites, rendering these sites resistant to cleavage.

Abstract: Provided are methods and kits for determining predisposition of a subject to develop a kidney disease, by identifying in a sample of the subject at least one APOL1 polypeptide variant which is characterized by a higher trypanolytic activity on Trypanosoma brucei rhodesiense as compared to the trypanolytic activity of wild type APOL1 polypeptide as set forth in SEQ ID NO:1 on the Trypanosoma brucei rhodesiense under identical assay conditions; or at least one APOL1 nucleotide mutation in the APLO1 genomic sequence set forth in SEQ ID NO:3, wherein the at least one nucleotide mutation or polypeptide variant being in linkage disequlibrium (LD) with the S342G mutation in the APOL1 polypeptide set forth in SEQ ID NO:1, wherein presence of the APOL1 polypeptide variant indicates increased predisposition of the subject to develop the kidney disease.

Abstract: A pharmaceutical composition and a method of treating, reducing or preventing vascular, cardiovascular arterial or valve calcification in a subject in need comprising administering to the subject an effective amount of an agent that prevents or reduces the expression of HDAC4, an agent that modulates the location of HDAC4, an agent that binds to HDAC4 or an inhibitor of HDAC4 or any combination thereof is provided. In some embodiments, there is provided a pharmaceutical composition comprising: an agent that prevents or reduces the expression of HDAC4, an agent that modulates the location of HDAC4, an agent that binds to HDAC4 or an inhibitor of HDAC4 or any combination thereof; an agent that prevents or reduces the expression of SIK or is an inhibitor of SIK; and/or an agent that prevents or reduces the expression of ENIGMA (Pdlim7) or is an inhibitor of ENIGMA.

Abstract: Provided are methods and kits for determining predisposition of a subject to develop a kidney disease, by identifying in a sample of the subject at least one APOL1 polypeptide variant which is characterized by a higher trypanolytic activity on Trypanosoma brucei rhodesiense as compared to the trypanolytic activity of wild type APOL1 polypeptide as set forth in SEQ ID NO:1 on the Trypanosoma brucei rhodesiense under identical assay conditions; or at least one APOL1 nucleotide mutation in the APLO1 genomic sequence set forth in SEQ ID NO:3, wherein the at least one nucleotide mutation or polypeptide variant being in linkage disequlibrium (LD) with the S342G mutation in the APOL1 polypeptide set forth in SEQ ID NO:1, wherein presence of the APOL1 polypeptide variant indicates increased predisposition of the subject to develop the kidney disease.

Abstract: Methods and kits for determining heparanase procoagulant activity in a biological sample are provided. Diagnostic methods for the detection and/or monitoring of a coagulation-related pathological disorder in a mammalian subject are further provided. In addition, compositions comprising heparanase and at least one tissue factor, uses and methods based thereon in the treatment, amelioration and prevention of coagulation-related pathologic conditions are provided. Also provided are methods for screening a coagulation modulatory compound, methods and uses based thereon in the treatment, amelioration and prevention of coagulation-related pathologic conditions.